Many companies possess a compound collection consisting of purified compounds and of unpurified products from combinatorial libraries. Using commercial and proprietary compounds as examples, this report provides clear examples of the significant impact purification can have on the activity observed for a compound and highlights the need to retest the purified compounds prior to creating structure-activity relationships. Crude mixtures made with commercial compounds led to an increase in the number of false positives in the SXR-GAL4 assay as compared with their pure and purified counterparts. An examination of proprietary compounds in an HIV assay resulted in the purification of 61 active crude synthetic mixtures. Of these 61 compounds, 32 were 5-fold less active and 2 were 5-fold more active after purification. This report details a semiautomated process developed and implemented for cherry-picking, tracking, and selectively purifying compounds found active in high-throughput screening campaigns. (Journal of Biomolecular Screening 2006:933-939) 
INTRODUCTION
T HE DEMAND FOR HIGH-THROUGHPUT SYNTHESIS, screening, and purification continues to remain important in the quest for new drugs. Combinatorial chemistry and high-throughput screening (HTS) are technologies that enable scientists to prepare and screen thousands of compounds and get the results quickly. Although it is preferable to screen only highly purified compounds, 1 until recently, 2, 3 it was impractical to purify large libraries, so crude products were screened and the active compounds in the interesting wells could be deduced either through fractionation and deconvolution 4 or through purification of the expected material. 5 Deconvolution is a time-consuming process that does not guarantee finding active components, let alone interesting ones around which further structure-activity relationship exploration may be done. Often it is preferred to isolate the expected compound from a crude synthetic mixture; as such, compounds are inherently more valuable than those identified through deconvolution because of the known synthetic tractability and the potential to access analogs through synthesis.
Although purification on the library scale is now possible, simply possessing the capability alone does not automatically justify making it the primary choice for handling all compounds on a high-throughput level. An analysis of the costs associated with purification, the amount of material synthesized, and the screening timelines may override the preference to screen only highly purified compounds. Therefore, it is likely that pharmaceutical companies will continue to produce interesting data using legacy libraries of unpurified reaction mixtures. With reported library hit rates in the range of 0.1% to 1%, 6 it is less expensive to reserve purification initially for those reaction mixtures whose activities reconfirm and then for any focused libraries subsequently produced around the active series.
Although there are a number of techniques that have proven useful for purification, chromatographic resolution generally provides highly pure compounds relatively quickly. In addition, the technology is amenable to automation and supports a variety of detectors with which to trigger fraction collection. Ultraviolet (UV)-triggered fraction collection is the most common technique used for automated purification because of its ease of use, the presence of UV chromophores on most druglike compounds, and its low cost. The drawback of UV-triggered purification is that 1 sample often results in the collection of multiple fractions, 7 something which quickly becomes a significant issue when purifying hundreds or thousands of compounds. In 1998, Zeng and Kassel unveiled preparative liquid chromatography/mass spectrometry (LC/MS), 8 a technique that reduced the number of fractions collected to 1 or 2 per injection by using a mass spectrometer to trigger fraction collection. Although literature reports have indicated high success rates with UV-triggered [9] [10] [11] or m/z-triggered 1,2,12 purification systems, the enhanced selectivity of the latter technique allows the collection of only the expected product (based on the m/z), making it more attractive for routine purification of larger numbers of compound solutions.
One of the challenges associated with m/z-triggered fraction collection is the selection of fraction collection thresholds. This is exacerbated when purifying only the compound solutions found to be active, as such compounds typically span multiple chemotypes, so generic gradients and triggering thresholds may not suffice, necessitating customized methods for purification. Manual creation of custom methods for purification usually is straightforward for a few samples from a small library but soon becomes impractical when faced with hundreds of samples scattered across numerous plates. Manual transfers, tracking, and method development cannot meet the needs of the scientists working in lead discovery, so it was necessary to have an efficient and dependable automated procedure. This report provides details on one such process and demonstrates the value of screening purified compounds. To our knowledge, there have been no previous reports demonstrating the value purification adds in eliminating false positives.
EXPERIMENTAL
A schematic of the process developed and implemented at our institute is shown in Figure 1 . Many of the steps shown in Figure  1 were designed to be workstation based, so the integration of the database with each of the sample-handling and -tracking steps proved critical for an efficient process.
Compound purification requests from scientists working in lead discovery
The compound request system was developed in house to enable scientists in lead discovery not only to place requests for particular compounds in the archive but also to request purification of compounds suspected of being impure.
Cherry-picking of requested compounds
The plates containing the requested compounds are retrieved and their bar codes scanned into an application that queried the compound database and generated work lists compatible with Gemini v3.4 SP1. All solution transfers were done using a TECAN RSP 200 (Tecan Group Ltd., Männedorf, Switzerland) liquid handler. After redissolution of the compounds in 0.5 mL of DMSO and several hours of shaking, the DMSO solutions were transferred from the library source plates to bar-coded 96deep-well plates (BD Biosciences, San Jose, CA). The source wells were marked as empty, and the contents of the destination plates were registered.
Generate LC/MS sample list and analytical LC/MS and analysis
Prepurification analysis of each of the cherry-picked samples was done to determine if the compound was present and if it could be purified under the eluent conditions. A 5 µL aliquot of each solution was transferred from the 96-well plates and added to 95 µL pure DMSO in a bar-coded 96-shallow-well plate. The samples were analyzed on an LC/MS system controlled by MassLynx 4. The system consisted of a 1525 highperformance liquid chromatography (HPLC) pump (Waters Corporation, Milford, MA), an HTS Pal autosampler with analytical and preparative injection valves (Leap Technologies, Carrboro, NC), a 2996 Diode Array UV detector (Waters Corporation), a Sedex 75 evaporative light-scattering detector (Richard Scientific, Novato, CA), a ZQ single quadrupole mass spectrometer (Waters Corporation), a 515 make-up HPLC pump (Waters Corporation), and a Fraction Collector II (Waters Corporation) The additional injection valve, 515 HPLC pump, and the Fraction Collector II allowed the system to switch automatically between analytical and preparative LC/MS.
All samples were analyzed on Atlantis C18 MS 50 × 2.0 mm ID columns (Waters Corporation). Eluents A and B were 0.05% spectrophotometric-grade trifluoroacetic acid (Sigma-Aldrich Chemicals, St. Louis, MO) in Milli-Q water and 0.05% spectrophotometric-grade trifluoroacetic acid in acetonitrile (Fisher Scientific, Fairlawn, NJ), respectively. The HPLC method consisted of a 0.5 min hold at 5% B and then a 3 min linear gradient from 5% to 95% B. This was followed by a 0.7 min column wash at 100% B and a 0.8 min column reequilibration at 5% B.
The prepurification LC/MS data for all the samples were uploaded to the institute's database so that the automated selection of LC/MS purification conditions could be achieved based on a series of rules.
Automated selection of LC/MS purification conditions
Automated selection of LC/MS purification conditions was accomplished based on chromatography zones and on empirical correlations observed between the extracted ion chromatograms (EICs) of the analytical and the preparative LC/MS data. According to earlier work, 13 the appropriate gradient can be determined when 2 separations are done for each mixture. Although with only 1 LC/MS chromatogram, a rigorous determination of the best conditions for separation is not possible, an estimate may be made based on the retention time and its relationship to the concentration of the stronger eluent present at the time the peak of interest eluted. Although the chromatographic separation under these conditions may not be ideal, it was used successfully to collect highly pure compounds when fraction collection was triggered by mass spectrometry. 12 Because the mass spectrometer was used to trigger fraction collection, it was critical to determine accurate triggering thresholds. In the course of purifying thousands of compounds, it was observed that a general correlation could be made between the maximum intensity observed in the EIC of the analytical chromatograms and the selection of thresholds in the corresponding preparative chromatograms. FractionLynx allows the user to create a large number of inlet method and fraction triggering files. Arbitrarily, up to 10 different gradients are available, with each focusing on a different zone in the 10% to 100% generic gradient used for the analytical LC/MS analyses. In addition, it was found that compounds with fraction trigger thresholds less than 10,000 or greater than 3,000,000 may provide too many fractions or may not have the required robustness. Thus, compounds that are calculated to have a fraction trigger of less than 10,000 are flagged for closer inspection and for possible purification using another technique. Those with a trigger greater than 3,000,000 are automatically reset to 3,000,000, the maximum permitted. In addition to these 2 triggers, another 14 fraction collection trigger files exist: 2E4, 3E4, . . . 1E6, and 2E6. By calculating the expected EIC for the preparative separation and rounding down to the nearest trigger value, an excellent correlation was found.
Purification
Because all the data needed to determine the purification conditions were based on the analytical data stored in the institute database and because the prepurification and purification plate bar codes were linked, creating the purification sample list required only that the bar code of the purification plate and its location on the autosampler be entered into an application tied to the database. The sample list generated contained file names, well locations, expected masses, the name of the inlet methods, and EIC triggering thresholds. To help reduce losses of these interesting compounds, the sample list generated for purification automatically excluded the flagged samples that were found to have a calculated threshold of less than 10,000 for fraction collection.
Purification usually was done using the 1-for-1 fraction collection mode to facilitate fraction tracking, postpurification sample processing, and sample assaying. When isomers were expected based on synthetic scheme and observed in the prepurification analytical LC/MS data, multiple fractions were collected to isolate the expected components from the mixture. No attempt was made to collect the effluent that was not collected by an m/z-trigger."
Postpurification sample handling and data tracking
After purification, the collected fractions were registered; transferred to tared, bar-coded 4.0-mL vials (Thomson Instrument Company, Oceanside, CA); and tracked in the Institute database. The vials were concentrated using a Savant Discovery rotary vacuum evaporator (Thermo Electron Corporation, Waltham, MA) and weighed on a Balance Automator outfitted with a SAG285 balance (Mettler-Toledo, Columbus, OH) to determine the micromoles collected. These data were uploaded to the institute database and used to create a dissolution work list for a Bohdan Universal Sample Prep instrument (Mettler-Toledo). After dissolution of the compounds to 10 mM in DMSO, aliquots of the purified compounds were transferred into plates for postpurification analysis and for delivery to biologists. The quality control plates were registered, and the LC/MS data collected were linked to the assay plate.
Assay details
SXR assay. Transcriptional assays were carried out using a GAL4-steroid and xenobiotic receptor (SXR) fusion construct containing the ligand-binding domain of the SXR receptor 14, 15 (amino acids 108-434) fused with the DNA-binding domain of GAL4 and a luciferase reporter construct containing 4 copies of the UAS G cloned upstream of the thymidine kinase promoter, both in pCDNA3 (Invitrogen, Carlsbad, CA). 15 HuH-7 human hepatoma cells were transfected with 0.12 µg/mL GAL4-SXR and 0.36 µg/mL reporter using Fugene 6 (Roche Molecular Systems, Inc., Pleasanton, CA), plated at 8000 cells/well of a 384-well plate in 50 µL of DMEM (Invitrogen) containing 3% charcoal-depleted fetal calf serum (Hyclone, Logan, UT) and 1% penicillin/streptomycin (Invitrogen), and incubated in a humidified incubator at 37°C in the presence of 5% CO 2 .
Just-in-Time Purification
Ligands were added 24 h later in 0.5 µL of DMSO. Luciferase activity was measured 28 h later using SteadyGlo (Promega, Madison, WI). Data were analyzed using Microsoft Excel and GraphPad Prism, and the results were normalized relative to pure rifampicin, the assay control.
HIV assay. This assay measures the ability of compounds to inhibit early events in HIV infection using a VSV-g pseudotyped HIV-1 luciferase reporter virus and has been described in detail elsewhere. 16 Briefly, compounds serially diluted in DMSO were added to adherent HEK293T target cells, followed by the VSV-g pseudotyped HIV-1 luciferase reporter virus. Luciferase activity was measured 48 h postinfection using Brite-Glo (Promega) and a chemiluminescence imaging plate reader (Molecular Devices, Sunnyvale, CA).
Solutions of commercially available compounds
To examine whether purification added any value relative to the quantification of the expected product in a crude reaction mixture, clofibrate, phenytoin, probenecid, dexamethasone, WY 14,643, fenofibrate, pregnenolone-16 alpha-carbonitrile (PCN), RU-486, clotrimazole, paclitaxel, rifampicin, and T0901317 (all from Sigma-Aldrich) were selected for a comparison of the assay results obtained when using solutions of differing quality but having the same concentration of the compound. Three solutions were made and tested for each compound: pure (commercial compound in DMSO), crude (commercial compound spiked into a crude combinatorial library to create a solution of approximately 85% purity), and purified (the isolated product purified from an aliquot of the crude solution).
RESULTS
Representative results obtained from assaying these compounds in the SXR assay are provided in Figure 2 , and a more comprehensive comparison of the activities is given in Table 1 . It was striking that the crude mixtures for clofibrate, phenytoin, probenecid, fenofibrate, and PCN showed significantly greater SXR activity than samples of the same compounds that were tested as pure or as purified solutions. For this small test set, 80% of the purified compounds yielded results comparable to those of the pure solutions. These results support the claim 17 that data obtained using purified compounds are more reliable than data obtained using crude mixtures.
To extend this comparison to proprietary compounds, 61 crude reaction mixtures that were found to be active against a previously reported replication defective HIV-1 16 were purified and retested. The results of this comparison, summarized in Figure 3 , demonstrate that higher concentrations of purified compounds were required to obtain the same activity that was observed with the crude synthetic mixtures. Interestingly, after purification, 32 of the 61 (52%) compounds were 5-fold less active and 2 were at least 5-fold more active.
DISCUSSION
Because of the drive to shorten the time in the discovery of high-quality leads, the time investment associated with purification sometimes is questioned, particularly when, based on their LC/MS analysis, the crude products appear to be relatively pure. Crude reaction mixtures may contain compounds with reactive functionalities, 18 for example, unreacted synthetic intermediates and/or residual reagents that may contribute to the observed activity. It has been reported that UV and evaporative light-scattering 
The symbols, -, +, ++, +++, and ++++ denote 0%-10%, 10%-20%, 20%-40%, 40%-60%, and >60% activity, respectively, relative to the control (rifampicin).
detectors do not detect all the components in a mixture 19, 20 and that the relative purities determined by these detectors may not accurately reflect the true purity of the sample. Often, reagents used in medicinal chemistry consist of relatively volatile, lowmolecular-weight compounds lacking UV chromophores in the 220-to 400-nm range, making them virtually undetectable by LC/MS techniques typically employed in drug discovery. It has been our experience that these invisible impurities can account for a large percentage of the false positives encountered, making the isolation of the expected compound(s) from a reaction mixture imperative to link the observed activity to the expected compound(s). Although it can be argued that the activity observed in a crude synthetic mixture may be due to an unexpected side product and, if so, that the structure of the side product should be determined, this generally is impractical for a large number of samples. As the number of compounds in the purification queue for a project increases, the need to investigate possible activity of the side products is diminished.
If the purified expected product failed to demonstrate activity comparable to that observed with the crude mixture, it was assumed that the initial activity was due to the presence of an impurity, and the compound was removed from further followup activity. Although many scientists make this assumption, there were no data in the literature supporting this. In particular, it was of interest to examine the differences in biological activities among pure, crude, and purified solutions when the concentration of each compound was kept constant under these 3 conditions. Because the model for the crude reaction mixtures was based on spiking a known amount of each compound into different wells of a random selection of failed chemistries, different crude solutions may be expected to give different results in the SXR assay, as shown in Table 1 for clofibrate, phenytoin, probenecid, dexamethasone, WY 14,643, clotrimazole, and paclitaxel. After purification, each of the isolated samples for each replicate of clofibrate, phenytoin, WY 14,643, clotrimazole, and paclitaxel was in agreement with the other and with the pure solutions. The purified solutions of probenecid and dexamethasone showed some variance, but the purified compounds were found to more closely resemble the pure solutions, indicating an improvement in solution quality.
Because it was demonstrated that purification of compounds leads to improved results (i.e., results in better agreement with those obtained using pure solutions), the process in Figure 1 was applied to the more relevant identification of active compounds in drug discovery assays. When older combinatorial libraries were assayed against HIV, 61 solutions were identified as having EC 50 values less than 2 µM. As shown in Figure 3 , many of the compound solutions had reduced activity after purification. Although the differences observed in activity between the crude and the purified compound may not be significant when the initial activity is low nanomolar, some of the prepurification solutions had EC 50 values in the range of 1 µM, whereas their purified solutions had EC 50 values in the range of 10 µM. Compounds that retain or show enhanced activity after purification may provide a starting point for medicinal chemistry efforts. It should be noted that although purification typically is done by a medicinal chemist, the purification work in this report was done at the earlier stages of hit and lead identification, before lead optimization and before the initiation of medicinal chemistry involvement. Figure 1 provides an outline for a robust and scalable semiautomated process for performing a large number of purifications over a range of chemotypes. By analyzing all samples prior to purification, it is possible to determine automatically if the chromatographic and ionization conditions are appropriate for successful sample purification and to exclude those that have a high likelihood of failing automated purification. This allows the purification scientist to deliver quickly the samples amenable to routine processing and to flag the more challenging samples for further method development. A 75% increase in efficiency has been found for processing routine samples without any difference in the purification success rates when decided by an expert or by the automated procedures reported, thereby making this a true improvement in efficiency.
CONCLUSIONS
This report describes a semiautomated process for requesting, cherry-picking, purifying, and preparing compounds for biological screening. The Institute database was a key component that allowed streamlining of the process because it performed all tracking and automated analysis functions. By automating the key steps in liquid handling, the error rate in sample processing and the time required for sample preparation was decreased and made less tedious. The implementation of a rules-based approach for purification reduced the time spent analyzing prepurification data by approximately 75% while maintaining the same purification success rate.
By comparing assay results for commercially available compounds as pure solutions and as crude mixtures tested before and after purification, it was demonstrated that the purified compound solutions had activity in the SXR assay that more closely matched those of the pure solutions. Results obtained using proprietary compounds in an HIV assay found that 56% of the compounds tested had differences of at least a factor of 5 in the EC 50 values determined before and after purification. It is important to note that no correlation could be made between the purities and activities of the crude mixtures with the activities of the purified compounds, indicating that the compound solutions need to be purified to ensure accurate assay results and optimal correlation of structure with activity.
